Inovio Pharmaceuticals, Inc. (INO)
1.43
+0.07
(+5.15%)
USD |
NASDAQ |
Sep 04, 16:00
1.42
-0.01
(-0.70%)
After-Hours: 20:00
Inovio Pharmaceuticals Research and Development Expense (Quarterly) : 10.50M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.50M |
| March 31, 2026 | 13.75M |
| December 31, 2025 | 9.921M |
| September 30, 2025 | 12.98M |
| June 30, 2025 | 14.17M |
| March 31, 2025 | 15.35M |
| December 31, 2024 | 12.89M |
| September 30, 2024 | 18.73M |
| June 30, 2024 | 23.09M |
| March 31, 2024 | 20.91M |
| December 31, 2023 | 17.25M |
| September 30, 2023 | 15.50M |
| June 30, 2023 | 23.74M |
| March 31, 2023 | 30.18M |
| December 31, 2022 | 42.12M |
| September 30, 2022 | 33.09M |
| June 30, 2022 | 56.46M |
| March 31, 2022 | 55.98M |
| December 31, 2021 | 92.30M |
| September 30, 2021 | 47.09M |
| June 30, 2021 | 70.81M |
| March 31, 2021 | 39.04M |
| December 31, 2020 | 26.30M |
| September 30, 2020 | 26.46M |
| June 30, 2020 | 22.38M |
| Date | Value |
|---|---|
| March 31, 2020 | 19.11M |
| December 31, 2019 | 22.00M |
| September 30, 2019 | 19.14M |
| June 30, 2019 | 22.49M |
| March 31, 2019 | 24.39M |
| December 31, 2018 | 26.37M |
| September 30, 2018 | 21.85M |
| June 30, 2018 | 22.46M |
| March 31, 2018 | 24.58M |
| December 31, 2017 | 24.64M |
| September 30, 2017 | 25.51M |
| June 30, 2017 | 23.88M |
| March 31, 2017 | 24.54M |
| December 31, 2016 | 23.91M |
| September 30, 2016 | 26.98M |
| June 30, 2016 | 19.63M |
| March 31, 2016 | 18.19M |
| December 31, 2015 | 15.60M |
| September 30, 2015 | 16.08M |
| June 30, 2015 | 16.69M |
| March 31, 2015 | 9.426M |
| December 31, 2014 | 9.244M |
| September 30, 2014 | 7.018M |
| June 30, 2014 | 9.607M |
| March 31, 2014 | 8.226M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Fortress Biotech, Inc. | 0.805M |
| Tonix Pharmaceuticals Holding Corp. | 19.42M |
| Kura Oncology, Inc. | 61.89M |
| Spero Therapeutics, Inc. | 3.434M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |